Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06609876
NA
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
Sponsor: Sun Yat-sen University
View on ClinicalTrials.gov
Summary
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
Official title: Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
108
Start Date
2024-10-01
Completion Date
2028-10-01
Last Updated
2024-12-03
Healthy Volunteers
No
Interventions
PROCEDURE
Thermal ablation
Thermal ablation of tumors
DRUG
Donafenib
Donafenib ( 100 mg,bid)
Locations (1)
Chinese PLA General hospital
Beijing, None Selected, China